Infections Caused by Stenotrophomonas maltophilia in Recipients of Hematopoietic Stem Cell Transplantation

KA Al-Anazi, AM Al-Jasser - Frontiers in oncology, 2014 - frontiersin.org
Stenotrophomonas maltophilia (S. maltophilia) is a globally emerging Gram-negative
bacillus that is widely spread in environment and hospital equipment. Recently, the …

Infections Caused by Acinetobacter baumannii in Recipients of Hematopoietic Stem Cell Transplantation

KA Al-Anazi, AM Al-Jasser - Frontiers in oncology, 2014 - frontiersin.org
Acinetobacter baumannii (A. baumannii) is a Gram-negative, strictly aerobic, non-
fermentative coccobacillus, which is widely distributed in nature. Recently, it has emerged as …

Clinical efficacy and safety of the combination of colistin plus vancomycin for the treatment of severe infections caused by carbapenem-resistant Acinetobacter …

J Garnacho-Montero, R Amaya-Villar… - Chemotherapy, 2014 - karger.com
A potent synergy of a glycopeptide-colistin combination against Acinetobacter baumannii
has recently been described. We set out to assess the efficacy and safety of this combination …

Colistin/daptomycin: an unconventional antimicrobial combination synergistic in vitro against multidrug-resistant Acinetobacter baumannii

I Galani, K Orlandou, H Moraitou, G Petrikkos… - International journal of …, 2014 - Elsevier
The in vitro activity of the combination colistin/daptomycin was evaluated against multidrug-
resistant Acinetobacter baumannii clinical isolates. Clonal relationships were assessed by …

Combination Therapy in Severe Acinetobacter Baumannii Infections: An Update on the Evidence to Date

E Durante-Mangoni, R Utili, R Zarrilli - Future Microbiology, 2014 - Taylor & Francis
Acinetobacter baumannii is a drug-resistant Gram-negative pathogen increasingly causing
hospital-acquired infections in critically ill patients. In this review, we summarize the current …

A Review of Novel Combinations of Colistin and Lipopeptide or Glycopeptide Antibiotics for the Treatment of Multidrug-Resistant Acinetobacter baumannii

KC Claeys, AD Fiorvento, MJ Rybak - Infectious diseases and therapy, 2014 - Springer
As antibiotic resistance continues to increase among Gram-negative organisms such as
Acinetobacter baumannii there is a growing need for novel therapies to overcome these …

Activity of the type I signal peptidase inhibitor MD3 against multidrug-resistant Gram-negative bacteria alone and in combination with colistin

Y Personne, MA Curtis, DW Wareham… - Journal of …, 2014 - academic.oup.com
Abstract Objectives Effective treatment of Gram-negative bacterial infections is increasingly
challenging due to the spread of multidrug-resistant strains and a lack of new antimicrobials …

Efficacy of the small molecule inhibitor of Lipid II BAS00127538 against Acinetobacter baumannii

EPH de Leeuw - Drug design, development and therapy, 2014 - Taylor & Francis
Objective To test the activity of a small molecule compound that targets Lipid II against
Acinetobacter baumannii. Methods Susceptibility to small molecule Lipid II inhibitor …

Efficacy of telavancin, a lipoglycopeptide antibiotic, in experimental models of Gram-positive infection

SS Hegde, JW Janc - Expert Review of Anti-infective Therapy, 2014 - Taylor & Francis
Telavancin is a parenteral lipoglycopeptide antibiotic with a dual mechanism of action
contributing to bactericidal activity against multidrug-resistant Gram-positive pathogens. It …

[PDF][PDF] Update on colistin in clinical practice

WA Alfahad, AS Omrani - Saudi Med J, 2014 - researchgate.net
ABSTRACT يريرسلا مادختسلإا مهف يف ًاريبك ًامدقت ريخلأا دقعلا دهش تاعرلجا مادختسإ ةرورض
اهنمو، ينتسيلوكلا تابكرلم لثملأا ةفعاضم ةيئدبم تاعرج ءاطعإ ةيمهأ ىلإ ةفاضلإاب ةيلاعلا …